Literature DB >> 8924916

Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.

A Odani1, Y Hashimoto, K Takayanagi, Y Otsuki, T Koue, M Takano, M Yasuhara, H Hattori, K Furusho, K Inui.   

Abstract

The population pharmacokinetic parameters of phenytoin were estimated using routine therapeutic drug monitoring data from 116 epileptic patients. The 531 serum concentration values at steady-state after repetitive oral administration were analyzed using a nonlinear mixed effects model (NONMEM) program designed for estimation of population pharmacokinetic parameters. A one-compartment model with dose-dependent clearance was used for the pharmacokinetic analysis of phenytoin. The volume of distribution (V) was estimated to be 1.231/kg in a typical 42-kg patient, assuming that the bioavailability of orally administered phenytoin is 100%. The maximal elimination rate (V(max)) and the Michaelis-Menten constant (K(m)) were 9.80 mg/d/kg and 9.19 micrograms/ml, respectively. The parameter of power function of weight to adjust V and V(max) was estimated to be 0.463. In addition, K(m) for phenytoin appeared to be 16% increased in patients receiving zonisamide concurrently. The population pharmacokinetic parameters of phenytoin will be useful for designing dosage regimens in epileptic patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924916     DOI: 10.1248/bpb.19.444

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

Review 1.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

2.  Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.

Authors:  Sven C van Dijkman; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2017-11-07       Impact factor: 4.335

3.  Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.

Authors:  Sachiyo Hashi; Ikuko Yano; Mai Shibata; Satohiro Masuda; Masako Kinoshita; Riki Matsumoto; Akio Ikeda; Ryosuke Takahashi; Kazuo Matsubara
Journal:  Eur J Clin Pharmacol       Date:  2014-10-18       Impact factor: 2.953

Review 4.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.

Authors:  Jun Tanaka; Hidefumi Kasai; Kenji Shimizu; Shigeki Shimasaki; Yuji Kumagai
Journal:  Eur J Clin Pharmacol       Date:  2012-08-24       Impact factor: 2.953

6.  Development and Validation of Open-Source R Package HMCtdm for Therapeutic Drug Monitoring.

Authors:  Sooyoung Lee; Moonsik Song; Woojae Lim; Eunjung Song; Jongdae Han; Bo-Hyung Kim
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-21

7.  Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling.

Authors:  Heajin Jun; Yan Rong; Catharina Yih; Jordan Ho; Wendy Cheng; Tony K L Kiang
Journal:  Drugs R D       Date:  2020-10-07

8.  A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure.

Authors:  Abhishek G Sathe; Richard C Brundage; Vijay Ivaturi; James C Cloyd; James M Chamberlain; Jordan J Elm; Robert Silbergleit; Jaideep Kapur; Lisa D Coles
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.